Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10%

Immunic, Inc. (NASDAQ:IMUX) is one of the stocks under $1 that will explode.

An array of pharmaceutical pills with the company’s logo on the bottle.

Immunic, Inc. (NASDAQ:IMUX) has recently demonstrated strong share price momentum, with its shares up 24.10% in the past five days as of the market open on January 9, 2026.

Amid the share price surge, the company’s management reviewed 2025 performance and outlined upcoming milestones, issuing a press release on January 7, 2026.

The company reflected on progress across both neurologic and gastrointestinal programs, with CEO Dr. Daniel Vitt emphasizing completion of enrollment in the twin Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS). Enrollment randomized 1,121 and 1,100 patients across more than 100 sites in 15 countries. Management highlighted a synchronized top-line readout to assess the therapy’s potential to modify disease progression by combining neuroprotective Nurr1 activation with selective DHODH inhibition. The readout is expected by the end of 2026.

Meanwhile, durable disability protection was confirmed by long-term Phase 2 EMPhASIS data in relapsing-remitting MS (RRMS). Over 92% of patients remained free of 24-week confirmed disability worsening after up to 5.5 years. A favorable safety profile was also reported.

On the other hand, data from the Phase 2 CALLIPER trial in progressive MS showed statistically significant reductions in 24-week confirmed disability worsening (24wCDW) and consistent trends across subtypes. The results support neuroprotective effects independent of inflammation.

Management also discussed IMU-856, an orally available and systemically acting small molecule modulator that targets Sirtuin 6 (SIRT6). The modulator showed promising early clinical and preclinical signals for gastrointestinal barrier restoration and weight management. With this, the company looks to expand its oral immunology portfolio on the back of strong financing in 2025, including a $65 million public offering, providing resources to advance these programs.

Immunic, Inc. (NASDAQ:IMUX) is focused on developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis, ulcerative colitis, and Crohn’s disease.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.